Kazimi A J's Form 4 filing
Cumberland Pharmaceuticals Inc (CPIX) · filed Jan 7, 2022
- Accession no.
- 0001209191-22-002457
- Filed
- Jan 7, 2022
- Trade date
- Dec 1-20, 2021
- Filing delay
- 37 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 14 non-derivative transactions. Open-market purchases total $1.79K. It was filed 37 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kazimi A JCIK 0001075050 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | Common Stock | PPurchaseAcquired | +18 | $4.14 | +$74.52 | 5,770,187 | Direct | |
| Dec 2, 2021 | Common Stock | PPurchaseAcquired | +18 | $3.84 | +$69.12 | 5,770,205 | Direct | |
| Dec 3, 2021 | Common Stock | PPurchaseAcquired | +18 | $4.47 | +$80.46 | 5,770,223 | Direct | |
| Dec 6, 2021 | Common Stock | PPurchaseAcquired | +18 | $4.46 | +$80.28 | 5,770,241 | Direct | |
| Dec 7, 2021 | Common Stock | PPurchaseAcquired | +18 | $5.61 | +$100.98 | 5,770,259 | Direct | |
| Dec 8, 2021 | Common Stock | PPurchaseAcquired | +18 | $6.15 | +$110.7 | 5,770,277 | Direct | |
| Dec 9, 2021 | Common Stock | PPurchaseAcquired | +18 | $5.81 | +$104.58 | 5,770,295 | Direct | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +18 | $4.82 | +$86.76 | 5,770,313 | Direct | |
| Dec 13, 2021 | Common Stock | PPurchaseAcquired | +30 | $4.36 | +$130.8 | 5,770,343 | Direct | |
| Dec 14, 2021 | Common Stock | PPurchaseAcquired | +30 | $4.28 | +$128.4 | 5,770,373 | Direct | |
| Dec 15, 2021 | Common Stock | PPurchaseAcquired | +30 | $4.29 | +$128.7 | 5,770,403 | Direct | |
| Dec 16, 2021 | Common Stock | PPurchaseAcquired | +50 | $4.53 | +$226.5 | 5,770,453 | Direct | |
| Dec 17, 2021 | Common Stock | PPurchaseAcquired | +50 | $4.17 | +$208.5 | 5,770,503 | Direct | |
| Dec 20, 2021 | Common Stock | PPurchaseAcquired | +60 | $4.33 | +$259.8 | 5,770,563 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.